ORY-2001 Low dose + ORY-2001 High dose + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild to Moderate Alzheimer's Disease
Conditions
Mild to Moderate Alzheimer's Disease
Trial Timeline
May 16, 2019 → Nov 12, 2020
NCT ID
NCT03867253About ORY-2001 Low dose + ORY-2001 High dose + Placebo
ORY-2001 Low dose + ORY-2001 High dose + Placebo is a phase 2 stage product being developed by Oryzon Genomics for Mild to Moderate Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03867253. Target conditions include Mild to Moderate Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03867253 | Phase 2 | Completed |
Competing Products
20 competing products in Mild to Moderate Alzheimer's Disease